Dataset Information

De novo EIF2AK1 and EIF2AK2 Variants Are Associated with Developmental Delay, Leukoencephalopathy, and Neurologic Decompensation.

ABSTRACT: EIF2AK1 and EIF2AK2 encode members of the eukaryotic translation initiation factor 2 alpha kinase (EIF2AK) family that inhibits protein synthesis in response to physiologic stress conditions. EIF2AK2 is also involved in innate immune response and the regulation of signal transduction, apoptosis, cell proliferation, and differentiation. Despite these findings, human disorders associated with deleterious variants in EIF2AK1 and EIF2AK2 have not been reported. Here, we describe the identification of nine unrelated individuals with heterozygous de novo missense variants in EIF2AK1 (1/9) or EIF2AK2 (8/9). Features seen in these nine individuals include white matter alterations (9/9), developmental delay (9/9), impaired language (9/9), cognitive impairment (8/9), ataxia (6/9), dysarthria in probands with verbal ability (6/9), hypotonia (7/9), hypertonia (6/9), and involuntary movements (3/9). Individuals with EIF2AK2 variants also exhibit neurological regression in the setting of febrile illness or infection. We use mammalian cell lines and proband-derived fibroblasts to further confirm the pathogenicity of variants in these genes and found reduced kinase activity. EIF2AKs phosphorylate eukaryotic translation initiation factor 2 subunit 1 (EIF2S1, also known as EIF2α), which then inhibits EIF2B activity. Deleterious variants in genes encoding EIF2B proteins cause childhood ataxia with central nervous system hypomyelination/vanishing white matter (CACH/VWM), a leukodystrophy characterized by neurologic regression in the setting of febrile illness and other stressors. Our findings indicate that EIF2AK2 missense variants cause a neurodevelopmental syndrome that may share phenotypic and pathogenic mechanisms with CACH/VWM.

SUBMITTER: Mao D

PROVIDER: S-EPMC7118694 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

De novo EIF2AK1 and EIF2AK2 Variants Are Associated with Developmental Delay, Leukoencephalopathy, and Neurologic Decompensation.

Mao Dongxue D Reuter Chloe M CM Ruzhnikov Maura R Z MRZ Beck Anita E AE Farrow Emily G EG Emrick Lisa T LT Rosenfeld Jill A JA Mackenzie Katherine M KM Robak Laurie L Wheeler Matthew T MT Burrage Lindsay C LC Jain Mahim M Liu Pengfei P Calame Daniel D Küry Sébastien S Sillesen Martin M Schmitz-Abe Klaus K Tonduti Davide D Spaccini Luigina L Iascone Maria M Genetti Casie A CA Koenig Mary K MK Graf Madeline M Tran Alyssa A Alejandro Mercedes M Lee Brendan H BH Thiffault Isabelle I Agrawal Pankaj B PB Bernstein Jonathan A JA Bellen Hugo J HJ Chao Hsiao-Tuan HT

American journal of human genetics 20200319 4

EIF2AK1 and EIF2AK2 encode members of the eukaryotic translation initiation factor 2 alpha kinase (EIF2AK) family that inhibits protein synthesis in response to physiologic stress conditions. EIF2AK2 is also involved in innate immune response and the regulation of signal transduction, apoptosis, cell proliferation, and differentiation. Despite these findings, human disorders associated with deleterious variants in EIF2AK1 and EIF2AK2 have not been reported. Here, we describe the identification o ...[more]

PMID: 32197074

Dataset Information

De novo EIF2AK1 and EIF2AK2 Variants Are Associated with Developmental Delay, Leukoencephalopathy, and Neurologic Decompensation.

Publications

De novo EIF2AK1 and EIF2AK2 Variants Are Associated with Developmental Delay, Leukoencephalopathy, and Neurologic Decompensation.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

<i>EIF2AK2</i>-related Neurodevelopmental Disorder With Leukoencephalopathy, Developmental Delay, and Episodic Neurologic Regression Mimics Pelizaeus-Merzbacher Disease.
| S-EPMC7862097 | biostudies-literature

De novo variants in EBF3 are associated with hypotonia, developmental delay, intellectual disability, and autism.
| S-EPMC5701309 | biostudies-literature

De novo variants in FRYL are associated with developmental delay, intellectual disability, and dysmorphic features.
| S-EPMC11023917 | biostudies-literature

De novo variants in MPP5 cause global developmental delay and behavioral changes.
| S-EPMC7906781 | biostudies-literature

De novo loss-of-function variants in STAG2 are associated with developmental delay, microcephaly, and congenital anomalies.
| S-EPMC7033032 | biostudies-literature

De novo mutations in PURA are associated with hypotonia and developmental delay.
| S-EPMC4850890 | biostudies-literature

De novo pathogenic variants in CHAMP1 are associated with global developmental delay, intellectual disability, and dysmorphic facial features.
| S-EPMC4849844 | biostudies-literature

De novo variants in GABRA4 are associated with a neurological phenotype including developmental delay, behavioral abnormalities and epilepsy.
| S-EPMC11291759 | biostudies-literature

De novo variants in FRMD5 are associated with developmental delay, intellectual disability, ataxia, and abnormalities of eye movement.
| S-EPMC9606480 | biostudies-literature

De Novo Variants in WDR37 Are Associated with Epilepsy, Colobomas, Dysmorphism, Developmental Delay, Intellectual Disability, and Cerebellar Hypoplasia.
| S-EPMC6699142 | biostudies-literature